List of Excipients in Branded Drug SOLTAMOX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayne Pharma	SOLTAMOX	tamoxifen citrate	51862-682	ALCOHOL
Mayne Pharma	SOLTAMOX	tamoxifen citrate	51862-682	ANISE
Mayne Pharma	SOLTAMOX	tamoxifen citrate	51862-682	GLYCERIN
Mayne Pharma	SOLTAMOX	tamoxifen citrate	51862-682	LICORICE
Mayne Pharma	SOLTAMOX	tamoxifen citrate	51862-682	PROPYLENE GLYCOL

Soltamox Excipient Strategy, Formulation IP and Commercial Opportunities

Last updated: October 14, 2026

Soltamox is a 10 mg/5 mL tamoxifen citrate oral solution. Its commercial value comes from dosage-form differentiation rather than a new active ingredient. The formulation is positioned for patients who cannot reliably swallow tablets, need flexible dosing, or require administration through a feeding tube. The core excipient strategy uses a sweetened, flavored aqueous vehicle with viscosity control, surfactant support, preservation and pH adjustment.[1]

The strongest opportunities are improved palatability, lower excipient burden, unit-dose packaging, feeding-tube compatibility, pediatric and adolescent risk-reduction applications, and international or specialty-pharmacy distribution. The principal risks are tamoxifen’s established generic status, limited formulation exclusivity, excipient tolerability and the difficulty of obtaining broad patent claims around a well-known oral solution.

What is Soltamox and how is it formulated?

Soltamox contains tamoxifen citrate equivalent to 10 mg tamoxifen in each 5 mL dose. It is supplied as an oral solution rather than a tablet.[1]

Soltamox composition

The FDA labeling identifies the following inactive ingredients:

Excipient	Formulation function	Commercial relevance
Glycerol	Co-solvent, humectant, mouthfeel modifier	Supports liquid consistency and sweetness
Sorbitol solution, 70%	Sweetener, bulking agent and viscosity contributor	Improves palatability but creates gastrointestinal and dietary-tolerance issues
Polysorbate 80	Surfactant and wetting agent	Supports uniformity and solubilization
Hydroxyethylcellulose	Viscosity modifier and suspending or consistency agent	Helps control pourability and dose uniformity
Sodium saccharin	High-intensity sweetener	Reduces the need for higher sugar loads
Benzoic acid	Preservative and pH-related excipient	Supports microbiological control
Citric acid	Acidulant and pH adjuster	Helps maintain product stability and taste
Flavoring agents	Taste masking	Important for adherence and repeat use

The formulation is designed around a multidose liquid product. Glycerol, sorbitol and sodium saccharin address sweetness and mouthfeel, while hydroxyethylcellulose controls physical properties. Polysorbate 80 supports product uniformity. Benzoic acid and citric acid provide preservation and pH control.[1]

The label should control all commercial formulation claims. Excipient grades, concentrations, manufacturing process parameters and packaging compatibility may not be fully disclosed in public labeling.

What patient and commercial problems does the Soltamox excipient system solve?

Soltamox addresses administration barriers that tablets do not solve efficiently.

The principal use cases are:

1. Patients with dysphagia or impaired swallowing.
2. Patients receiving medication through enteral feeding tubes.
3. Patients needing doses below or between available tablet strengths.
4. Patients who cannot consistently split or crush tablets.
5. Pediatric or adolescent patients requiring weight-based or titrated dosing.
6. Patients receiving long-term endocrine therapy who have adherence problems with solid dosage forms.

Liquid dosage forms can support dose flexibility, but they create new risks. Sorbitol can cause gastrointestinal discomfort, particularly at higher daily volumes. Patients with hereditary fructose intolerance may require special review because sorbitol can metabolize to fructose. The product also requires careful measurement and handling to avoid dose errors.

For a standard 20 mg daily dose, Soltamox requires 10 mL per day. That volume is manageable, but it is materially larger than one 20 mg tablet. A commercial successor could improve usability through a more concentrated formulation if bioequivalence, dose uniformity, stability and safety are established.

What excipient strategies could improve Soltamox?

The most attractive strategy is a next-generation liquid with fewer tolerability and administration limitations.

Sugar-free and lower-sorbitol formulations

A reformulation could reduce or remove sorbitol while retaining palatability through combinations of sucralose, acesulfame potassium, saccharin, xylitol or other suitable sweeteners. The objective would be to reduce gastrointestinal effects and improve use in patients who avoid polyols.

A lower-sorbitol formulation could support a differentiated label for patients with dietary or gastrointestinal concerns. The regulatory burden would include comparative stability, preservative effectiveness, microbial limits, taste assessment and clinical bridging.

Improved taste masking

Tamoxifen formulations can present bitterness or medicinal aftertaste. A development program could evaluate:

• Flavor systems compatible with acidic aqueous media.
• Polymer-based taste-masking systems.
• Ion-pairing or complexation approaches.
• Microencapsulated drug particles.
• Alternative sweetener combinations.
• Reduced residual taste after swallowing.

Taste masking is commercially relevant because tamoxifen therapy is chronic. A modest improvement in acceptability may have greater practical value than a small change in initial flavor intensity.

Concentrated oral solution

A 20 mg/mL or 40 mg/mL product could reduce administration volume. This may improve adherence and ease feeding-tube administration. The main technical barriers are solubility, precipitation, dose uniformity, preservative performance and accidental overdose risk.

A concentrated formulation could support a new device strategy, such as a calibrated oral syringe or metered dispenser. The device and formulation would need to be developed as an integrated product because delivery accuracy becomes more important as concentration increases.

Preservative-reduced or preservative-free products

Benzoic acid contributes to microbial protection but may affect taste and tolerability. A preservative-free unit-dose product could target hospitals, specialty pharmacies and patients with sensitivity concerns. The trade-off is greater packaging cost and stricter container-closure controls.

Unit-dose sachets, oral syringes or blow-fill-seal containers could reduce contamination risk and simplify dose administration. These formats could also reduce pharmacy measurement errors.

Feeding-tube optimized formulation

An enteral-use product should be evaluated for tube compatibility, clogging, adsorption, dilution, recovery and post-administration flushing. Polysorbate 80 and hydroxyethylcellulose can influence foam, viscosity and residue. A formulation optimized for feeding tubes could support institutional purchasing and home-care channels.

What formulation patents could protect a Soltamox successor?

A broad patent on tamoxifen oral solution is difficult to obtain because tamoxifen, liquid dosage forms and conventional excipients are established technologies. More defensible claims would focus on specific performance characteristics.

Potential patent claim categories

Claim category	Possible inventive focus
Composition	Defined tamoxifen concentration, sweetener ratio, pH and preservative system
Taste masking	Specific polymer, complex, flavor or bitterness-reduction system
Stability	Reduced precipitation, controlled degradation or extended shelf life
Delivery device	Metered dispenser or syringe calibrated for the formulation
Enteral administration	Low-residue, low-adsorption or anti-clogging formulation
Packaging	Light-protective, unit-dose or preservative-free container system
Manufacturing	Mixing order, temperature control, homogenization or filtration process
Use	Administration to patients unable to swallow tablets or through a feeding tube

A defensible patent position would require comparative data. Examples include improved taste scores, lower precipitation after dilution, superior tube recovery, longer stability, lower preservative concentration or improved dose accuracy.

A formulation patent should avoid relying only on routine excipient substitution. Claims are more durable when tied to a measurable technical effect and a narrow but commercially meaningful formulation window.

When does Soltamox lose exclusivity?

Tamoxifen is an established generic active ingredient, and the commercial exclusivity value of Soltamox depends primarily on its oral-solution formulation, regulatory status, manufacturing know-how and distribution relationships.

Soltamox received FDA approval under NDA 021807. The product’s commercial position is distinct from tamoxifen tablet products because tablets and oral solutions have different dosage forms and may not be directly substitutable at the pharmacy level.[1][2]

FDA regulatory exclusivity and patent exclusivity must be separated:

Protection type	Soltamox relevance
Active-ingredient patent	No meaningful remaining protection is expected for tamoxifen itself
Oral-solution formulation patent	Potentially relevant if an enforceable patent is listed or granted
Method-of-use patent	Could cover a specific population, dosing regimen or indication
FDA new-drug exclusivity	Historical approval-related exclusivity may have expired
Orange Book listing	Must be checked against the current FDA publication for active patents and exclusivity
Trade secrets	Manufacturing process, flavor system and supplier specifications may remain valuable

The Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with the NDA.[2] A commercial assessment should not treat the Soltamox brand alone as evidence of continuing market exclusivity.

What is the Orange Book and Paragraph IV status of Soltamox?

A generic applicant seeking approval of tamoxifen oral solution could use an ANDA if it can establish the required pharmaceutical equivalence and bioequivalence. If the reference product is protected by a listed patent, the applicant could submit a Paragraph IV certification challenging that patent.

The practical pathway depends on:

• Whether Soltamox is the reference listed drug for the proposed product.
• Whether the applicant can match dosage form and strength.
• Whether the product contains the same active ingredient form and inactive-ingredient profile where required.
• Whether an approved suitability petition or 505(b)(2) pathway is necessary.
• Whether any current Orange Book-listed patents remain enforceable.
• Whether the proposed labeling can avoid protected indications or dosing instructions.

A reformulated product with different excipients may be more suitable for a 505(b)(2) application than an ANDA if the sponsor relies on Soltamox or other FDA findings while introducing a materially different formulation or device.[3]

No Paragraph IV litigation, settlement agreement or generic launch event should be assumed without a current review of FDA records and federal court filings. The relevant litigation risk is likely to arise from a future improved formulation patent rather than from tamoxifen’s expired active-ingredient estate.

Which companies are challenging Soltamox?

The competitive threat is more likely to come from formulation developers and generic manufacturers than from biosimilar companies. Tamoxifen is a small molecule, so biosimilar pathways do not apply.

Potential competitors include:

• Generic manufacturers developing tamoxifen oral solution.
• Compounding pharmacies supplying extemporaneous liquid formulations.
• Specialty pharmaceutical companies developing pediatric or dysphagia products.
• Drug-delivery companies offering metered liquid systems.
• Manufacturers of tamoxifen tablets marketed for crushing or alternative administration, subject to product-specific regulatory and clinical considerations.

Compounded products may compete on price and customization but do not necessarily provide the same FDA-approved formulation, quality controls, stability data or commercial distribution infrastructure. An FDA-approved oral solution can retain value in institutional and specialty settings even where compounding is available.

What commercial opportunities exist for Soltamox excipient innovation?

The highest-value opportunities are concentrated in niche populations and channel-specific products.

Specialty and adherence markets

A more palatable formulation could target patients receiving five or more years of endocrine therapy. Oncology practices, specialty pharmacies and patient-support programs may value a product that reduces swallowing barriers and administration friction.

Pediatric and adolescent use

Tamoxifen is not primarily a pediatric commercial market, but liquid dosing can be useful where clinicians require weight-based or individualized administration. Any expansion would require appropriate clinical, labeling and safety support. Pediatric positioning should not rely solely on the existence of a liquid dosage form.

Hospital and home-care markets

A feeding-tube-compatible, unit-dose product could target hospitals, long-term-care facilities and home-care providers. Dose accuracy and reduced preparation time are stronger purchasing arguments than flavor alone.

International markets

Soltamox-style products may have opportunities in jurisdictions where tamoxifen tablets dominate but liquid products are unavailable. Geographic expansion would require country-specific registration, pediatric rules, excipient restrictions, labeling and local patent analysis.

Licensing opportunities

A sponsor could license:

• Taste-masking technology.
• Low-sorbitol or polyol-free excipient systems.
• Enteral-tube compatibility technology.
• Metered-dose liquid delivery devices.
• Unit-dose packaging.
• Regional rights for an improved oral solution.

The most practical structure would be a formulation or device license paired with territorial commercialization rights. A license based only on the Soltamox brand would have less value if it lacks enforceable formulation IP or regulatory exclusivity.

How strong is the Soltamox patent estate?

The patent estate is likely weak for the active ingredient and potentially moderate for a narrowly defined oral-solution improvement. The strongest protection would attach to a formulation with demonstrated technical advantages, a proprietary delivery device, or a manufacturing process that is difficult to design around.

Asset	Indicative strength
Tamoxifen active ingredient	Very weak or expired
Conventional sweetened oral solution	Weak
Specific taste-masking system	Moderate if supported by comparative data
Tube-compatible concentrated formulation	Moderate to strong if technically differentiated
Metered delivery system	Moderate, depending on device claims
Manufacturing process	Moderate as trade secret; patent strength depends on non-obviousness
Pediatric or adherence method claims	Variable and vulnerable to prior-art challenges

Manufacturing know-how may be more valuable than patents. The critical know-how can include excipient grade selection, mixing sequence, flavor compatibility, preservative effectiveness, filtration and container-closure performance.

What regulatory status applies to Soltamox?

Soltamox is an FDA-approved prescription drug product under NDA 021807.[1] It is a tamoxifen citrate oral solution, not a biologic. Biosimilar approval pathways are therefore irrelevant.

Future products could pursue:

• An ANDA for a pharmaceutically equivalent oral solution.
• A 505(b)(2) application for a materially different formulation, concentration, device or administration method.
• A supplemental NDA for changes to an existing approved product.
• A medical-food or compounded-product strategy only where legally appropriate, though these routes would not provide equivalent FDA drug approval.

Changes to sweeteners, preservatives, concentration, flavor, packaging or delivery devices can affect bioequivalence, stability, microbial control and labeling. Excipient changes should be assessed against FDA inactive-ingredient precedent, product-specific guidance and the FDA Inactive Ingredient Database.[3][4]

Key Takeaways

• Soltamox is a 10 mg/5 mL tamoxifen citrate oral solution approved under NDA 021807.
• Its value is dosage-form differentiation, not active-ingredient exclusivity.
• The current excipient system uses glycerol, sorbitol, polysorbate 80, hydroxyethylcellulose, sodium saccharin, benzoic acid, citric acid and flavoring.
• The strongest commercial opportunities are improved taste, reduced sorbitol, concentrated dosing, feeding-tube compatibility and unit-dose packaging.
• A generic oral solution could create competitive pressure if no enforceable formulation patents or regulatory exclusivity remain.
• Biosimilar competition does not apply because tamoxifen is a small molecule.
• New patent value would likely come from measurable technical effects, proprietary delivery devices or manufacturing know-how.
• The Orange Book and current FDA records control the assessment of listed patents, exclusivity and reference-product status.

FAQs

Can Soltamox excipients be changed without a new FDA approval?

No. A material change to excipients, concentration, preservative system, dosage device or packaging generally requires an FDA-regulated submission, with the pathway depending on the sponsor’s product and the extent of the change.

Is sorbitol in Soltamox a commercial liability?

It can be. Sorbitol supports sweetness and formulation performance, but gastrointestinal intolerance and dietary restrictions create an opportunity for a lower-sorbitol or polyol-free successor.

Can a concentrated tamoxifen oral solution be patented?

Potentially, but concentration alone may not be inventive. Patent strength would improve if the formulation solves precipitation, dose uniformity, stability, taste, tube compatibility or administration-volume problems.

Does Soltamox have biosimilar risk?

No. Biosimilars apply to biologic products. Tamoxifen competitors would use generic drug, 505(b)(2) or other small-molecule regulatory pathways.

Is a compounded tamoxifen liquid equivalent to Soltamox?

Not necessarily. Compounded products may differ in stability, excipient composition, quality controls, labeling and FDA approval status. They can compete commercially but do not automatically replicate the approved Soltamox product.

References

1. U.S. Food and Drug Administration. (n.d.). Soltamox (tamoxifen citrate) oral solution, prescribing information. NDA 021807.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

3. U.S. Food and Drug Administration. (n.d.). Guidance for industry: Applications covered by section 505(b)(2).

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.